Literature DB >> 18325780

Pharmacokinetics of fructose-1,6-diphosphate after intraperitoneal and oral administration to adult rats.

Kaiping Xu1, Janet L Stringer.   

Abstract

Exogenously administered fructose-1,6-diphosphate (FDP) has been studied for its ability to protect tissue during hypoxia or ischemia. Recently, a clear effect of FDP on the central nervous system has raised the question whether FDP can get into the brain. FDP levels were measured in blood, brain, liver, kidney, muscle and fat after intraperitoneal administration of a single 0.5gkg(-1) dose of FDP to adult male Sprague-Dawley rats. A complete time course of the levels in blood and brain was determined. The levels of FDP in the blood and brain increase simultaneously, i.e. there is no lag in the increase in the brain. The levels of FDP fall to baseline in liver, kidney, muscle and fat by 12h, but remain elevated in blood and brain. However, levels in the blood at 12h are significantly decreased from the peak levels, while those in brain are not different from the peak levels, suggesting that the kinetics of FDP in blood and brain are quite different. Stripping the endothelial cells from the brain tissue sample did not change the levels of FDP indicating that FDP is not trapped in the capillary cells. Incubation of brain slices in a solution of FDP, followed by washing, raised tissue levels of FDP indicating that FDP is taken up into cells within the brain. Finally, the experiments demonstrate a significant increase in brain levels of FDP after oral administration. These data suggest that an oral formulation of FDP might be developed for treatment of neurological disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18325780      PMCID: PMC2718754          DOI: 10.1016/j.phrs.2008.01.008

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  15 in total

1.  Fructose-1,6-bisphosphate supports cerebral energy metabolism in pigs after ischemic brain injury caused by experimental particle embolization.

Authors:  Timo Kaakinen; Janne Heikkinen; Sebastian Dahlbacka; Hanna Alaoja; Päivi Laurila; Kai Kiviluoma; Timo Salomäki; Pekka Romsi; Hannu Tuominen; Fausto Biancari; Pasi Lepola; Matti Nuutinen; Tatu Juvonen
Journal:  Heart Surg Forum       Date:  2006       Impact factor: 0.676

2.  Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins.

Authors:  D Triguero; J Buciak; W M Pardridge
Journal:  J Neurochem       Date:  1990-06       Impact factor: 5.372

3.  Potential therapeutic applications of fructose-1,6-diphosphate.

Authors:  P J Marangos; A W Fox; B J Riedel; D Royston; Z E Dziewanowska
Journal:  Expert Opin Investig Drugs       Date:  1998-04       Impact factor: 6.206

4.  Metabolic responses to fructose-1,6-diphosphate in healthy subjects.

Authors:  A K Markov; W A Neely; R H Didlake; J Terry; A Causey; P H Lehan
Journal:  Metabolism       Date:  2000-06       Impact factor: 8.694

5.  Improved brain metabolism with fructose 1-6 diphosphate during insulin-induced hypoglycemic coma.

Authors:  L A Farias; J Sun; A K Markov
Journal:  Am J Med Sci       Date:  1989-05       Impact factor: 2.378

6.  Pharmacokinetics of fructose-1, 6-diphosphate in the rat.

Authors:  M P Rigobello; L Galzigna
Journal:  Farmaco Sci       Date:  1982-07

7.  Prevention of ischemic-hypoxic brain injury and death in rabbits with fructose-1,6-diphosphate.

Authors:  L A Farias; E E Smith; A K Markov
Journal:  Stroke       Date:  1990-04       Impact factor: 7.914

8.  Metabolism of exogenously applied fructose 1,6-bisphosphate in hypoxic vascular smooth muscle.

Authors:  C D Hardin; T M Roberts
Journal:  Am J Physiol       Date:  1994-12

9.  Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats.

Authors:  Xiao-Yuan Lian; Firdous A Khan; Janet L Stringer
Journal:  J Neurosci       Date:  2007-10-31       Impact factor: 6.167

10.  Permeability of fructose-1,6-bisphosphate in liposomes and cardiac myocytes.

Authors:  Thomas J Wheeler; John M McCurdy; Aaron denDekker; Sufan Chien
Journal:  Mol Cell Biochem       Date:  2004-04       Impact factor: 3.396

View more
  7 in total

1.  Fructose-1,6-bisphosphate reduces the mortality in Candida albicans bloodstream infection and prevents the septic-induced platelet decrease.

Authors:  Roberto Christ Vianna Santos; Rafael Noal Moresco; Miguel Angel Peña Rico; Antonio R García Susperregui; Jose Luis Rosa; Ramon Bartrons; Francesc Ventura; Débora Nunes Mário; Sydney Hartz Alves; Etiane Tatsch; Helena Kober; Ricardo Obalski de Mello; Patrícia Scherer; Henrique Bregolin Dias; Jarbas Rodrigues de Oliveira
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

Review 2.  Possible mechanisms for the anticonvulsant activity of fructose-1,6-diphosphate.

Authors:  Janet L Stringer; Kaiping Xu
Journal:  Epilepsia       Date:  2008-11       Impact factor: 5.864

3.  Oral administration of fructose-1,6-diphosphate has anticonvulsant activity.

Authors:  Xiao-Yuan Lian; Kaiping Xu; Janet L Stringer
Journal:  Neurosci Lett       Date:  2008-12-03       Impact factor: 3.046

4.  Fructose-1,6-bisphosphate does not preserve ATP in hypoxic-ischemic neonatal cerebrocortical slices.

Authors:  Jia Liu; Kiyoshi Hirai; Lawrence Litt
Journal:  Brain Res       Date:  2008-08-12       Impact factor: 3.252

5.  Fructose 1,6-Bisphosphate as a Protective Agent for Experimental Fat Grafting.

Authors:  Tao Lv; Yunpeng Gu; Jianhai Bi; Ning Kang; Zhigang Yang; Xin Fu; Qian Wang; Li Yan; Xia Liu; Yilin Cao; Ran Xiao
Journal:  Stem Cells Transl Med       Date:  2019-02-18       Impact factor: 6.940

6.  Repeated febrile convulsions impair hippocampal neurons and cause synaptic damage in immature rats: neuroprotective effect of fructose-1,6-diphosphate.

Authors:  Jianping Zhou; Fan Wang; Jun Zhang; Hui Gao; Yufeng Yang; Rongguo Fu
Journal:  Neural Regen Res       Date:  2014-05-01       Impact factor: 5.135

7.  Fructose-1,6-bisphosphate prevents pulmonary fibrosis by regulating extracellular matrix deposition and inducing phenotype reversal of lung myofibroblasts.

Authors:  Henrique Bregolin Dias; Jarbas Rodrigues de Oliveira; Márcio Vinícius Fagundes Donadio; Shioko Kimura
Journal:  PLoS One       Date:  2019-09-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.